Inventor · disambiguated record
Wilfried Braje
Also filed as: BRAJE WILFRIED · BRAJE WILFRIED M · BRAJE WILFRIED MARTIN
62 granted patents·42 pending applications·173 citations·filing 2002–2024
98Inventor score
Top patents by PatentIndex Score
104 records- 0190US8703774B2Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseasesNETZ ASTRID·Filed 2008·Granted Apr 22, 2014·11 cites·17 claims
- 0290US8420670B24-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapyAMBERG WILHELM·Filed 2008·Granted Apr 16, 2013·17 cites·18 claims
- 0389US8546401B25,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseasesBRAJE WILFRIED·Filed 2008·Granted Oct 1, 2013·11 cites·25 claims
- 0488US8815868B2Substituted oxindole derivatives and their use as vasopressin receptor ligandsNETZ ASTRID·Filed 2007·Granted Aug 26, 2014·8 cites·55 claims
- 0588US8653100B2Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapyOCHSE MICHAEL·Filed 2009·Granted Feb 18, 2014·17 cites·20 claims
- 0688US8440694B2Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptorTURNER SEAN COLM·Filed 2012·Granted May 14, 2013·12 cites·13 claims
- 0787US10118926B2Tricyclic quinoline and quinoxaline derivativesABBVIE DEUTSCHLAND·Filed 2013·Granted Nov 6, 2018·10 cites·6 claims
- 0887US8859557B2Substituted oxindole derivatives and their use as vasopressin receptor ligandsNETZ ASTRID·Filed 2012·Granted Oct 14, 2014·7 cites·22 claims
- 0987US8703775B2Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnessesOOST THORSTEN·Filed 2008·Granted Apr 22, 2014·10 cites·14 claims
- 1087US6919342B2Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptorABBOTT GMBH & CO KG·Filed 2004·Granted Jul 19, 2005·17 cites·15 claims
- 1186US2025313572A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2024·Application pending·0 cites
- 1283US9527856B2Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseasesABBVIE DEUTSCHLAND·Filed 2015·Granted Dec 27, 2016·4 cites·38 claims
- 1382US2024228509A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2023·Application pending·0 cites
- 1481US2025092062A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2024·Application pending·0 cites
- 1580US7790727B2Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptorABBOTT GMBH & CO KG·Filed 2008·Granted Sep 7, 2010·4 cites·31 claims
- 1678US8664214B2Small molecule potentiators of metabotropic glutamate receptors IBRAJE WILFRIED·Filed 2011·Granted Mar 4, 2014·5 cites·19 claims
- 1778US2023399340A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2022·Application pending·0 cites
- 1877US9242933B2Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor)GENESTE HERVE·Filed 2008·Granted Jan 26, 2016·3 cites·18 claims
- 1977US8629148B2Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnessesBRAJE WILFRIED·Filed 2008·Granted Jan 14, 2014·2 cites·32 claims
- 2077US2022259226A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2022·Application pending·0 cites
- 2176US7851463B2Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptorABBOTT GMBH & CO KG·Filed 2005·Granted Dec 14, 2010·2 cites·21 claims
- 2276US7320979B2N-[(piperazinyl)hetaryl]arylsulfonamide compoundsABBOTT GMBH & CO KG·Filed 2004·Granted Jan 22, 2008·7 cites·22 claims
- 2375US9169253B2Tricyclic quinoline and quinoxaline derivativesABBVIE DEUTSCHLAND·Filed 2013·Granted Oct 27, 2015·1 cites·23 claims
- 2475US2023183261A1Macrocyclic MCL-1 Inhibitors and Methods of UseABBVIE INC·Filed 2022·Application pending·0 cites
- 2574US9023854B25-halogen-substituted oxindole derivatives and use thereof for treating vasopressin-dependent diseasesBRAJE WILFRIED·Filed 2008·Granted May 5, 2015·1 cites·34 claims
- 2674US8518933B2Modulators of 5-HT receptors and methods of use thereofWANG YING·Filed 2010·Granted Aug 27, 2013·2 cites·9 claims
- 2774US8242102B2Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptorTURNER SEAN COLM·Filed 2008·Granted Aug 14, 2012·2 cites·23 claims
- 2873US10836688B2Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcelluloseABBVIE DEUTSCHLAND·Filed 2020·Granted Nov 17, 2020·1 cites·20 claims
- 2973US9573950B2Substituted [1,4]diazepino[6,7,1-ij]quinolines as serotonin 5-HT2C receptor modulatorsABBVIE DEUTSCHLAND·Filed 2015·Granted Feb 21, 2017·2 cites·48 claims
- 3073US9422264B2Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseasesABBVIE DEUTSCHLAND·Filed 2014·Granted Aug 23, 2016·1 cites·21 claims
- 3173US8969552B2Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptorDRESCHER KARLA·Filed 2005·Granted Mar 3, 2015·2 cites·25 claims
- 3273US7960386B2Pyridin-2-one compounds and their use as modulators of the dopamine D3 receptorABBOTT GMBH & CO KG·Filed 2005·Granted Jun 14, 2011·1 cites·12 claims
- 3371US8957089B2Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapyABBVIE DEUTSCHLAND·Filed 2013·Granted Feb 17, 2015·1 cites·15 claims
- 3471US8546377B2Modulators of 5-HT receptors and methods of use thereofWANG YING·Filed 2010·Granted Oct 1, 2013·2 cites·17 claims
- 3571US8314120B2Small molecule potentiators of metabotropic glutamate receptorsBRAJE WILFRIED·Filed 2011·Granted Nov 20, 2012·2 cites·32 claims
- 3671US8232426B2Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptorDRESCHER KARLA·Filed 2005·Granted Jul 31, 2012·1 cites·19 claims
- 3770US2021292339A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2020·Application pending·0 cites
- 3868US8507469B2Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptorSCHULTZ THOMAS·Filed 2008·Granted Aug 13, 2013·2 cites·44 claims
- 3968US2020325153A1Macrocyclic MCL-1 Inhibitors and Methods of UseABBVIE INC·Filed 2020·Application pending·0 cites
- 4067US8008488B2Pyrimidin-2-one compounds and their use as dopamine D3 receptor ligandsABBOTT GMBH & CO KG·Filed 2004·Granted Aug 30, 2011·3 cites·20 claims
- 4165US8101754B2Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptorUNGER LILIANE·Filed 2005·Granted Jan 24, 2012·1 cites·21 claims
- 4265US2020255451A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2018·Application pending·0 cites
- 4365US2019055264A1Macrocyclic MCL-1 inhibitors and methods of useABBVIE INC·Filed 2018·Application pending·0 cites
- 4465US2020239494A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2018·Application pending·0 cites
- 4564US2020010480A1Macrocyclic MCL-1 Inhibitors and Methods of UseABBVIE INC·Filed 2019·Application pending·0 cites
- 4664US2014080813A1Tricyclic quinoline and quinoxaline derivativesABBVIE DEUTSCHLAND·Filed 2013·Application pending·0 cites
- 4764US2019048007A1Tricyclic quinoline and quinoxaline derivativesABBVIE DEUTSCHLAND·Filed 2018·Application pending·0 cites
- 4863US2014378471A1Substituted oxindole derivatives and their use as vasopressin receptor ligandsABBOTT GMBH & CO KG·Filed 2014·Application pending·0 cites
- 4962US7723384B2Keto lactam compounds and use thereofABBOTT GMBH & CO KG·Filed 2004·Granted May 25, 2010·1 cites·19 claims
- 5061US9701679B2Modulators of 5-HT receptors and methods of use thereofABBVIE DEUTSCHLAND·Filed 2014·Granted Jul 11, 2017·0 cites·9 claims
Showing the top 50 of 104 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →